What is the study testing?

The PROSPECT-2 Study is testing an investigational medicine called eptinezumab to see if it can safely prevent migraine headaches in adolescents and teens 12 to 17 years old. Researchers want to know if eptinezumab can safely reduce the number of headache days.

Learn more about the study.

Understanding the PROSPECT-2 Study

Watch the videos below to learn more about the PROSPECT-2 Study.

For Adults & Caregivers

For Ages 12-17

Illustration of an Afircan-American female doctor holding a tablet with icons representing chronic migraine in teens.

Who can participate in the study?

To be considered for the PROSPECT-2 Study, your child must:

  • Be 12 to 17 years of age.
  • Have at least a 6-month history of chronic migraine.

What treatment will my child receive?

During the study, your child will receive either the study medicine, eptinezumab, or a placebo. The placebo looks like eptinezumab but contains no actual medicine. This gives researchers something to compare with the study medicine.

What happens during the study?

The main part of the study lasts about 16 weeks (4 months). During this time your child will receive study treatment and have study site visits for tests and health checks.

Orange circle with the number one inside it, Screening, lasts 4 weeks

Screening

(lasts 4 weeks)

Before starting, you will need to give permission for your child to join by signing the Informed Consent Form.

Your child will have 1 visit at which the study doctor will ask about your child’s health, medicines he/she takes, and run tests to make sure your child is eligible for the study.


Orange circle with the number two inside it, Headache Tracking

Headache tracking

Your child will be given an electronic diary to keep track of headaches for 4 weeks before starting treatment to make sure the study is right for him/her. If it is, your child will continue to track headaches throughout the 12-week study treatment period.


Orange circle with the number three inside it, Study Treatment, lasts 12 weeks

Study treatment

(lasts 12 weeks)

If your child is eligible, he/she will be placed by chance into a group to receive either eptinezumab or placebo. The placebo looks like eptinezumab but contains no actual medicine. This gives researchers something to compare with the study medicine. To help keep the study fair, neither you nor the study team will know which group your child is in.

Your child will receive eptinezumab or placebo as a one-time infusion that takes about 30 minutes.

Your child will have 2 phone calls and 3 study visits to check on his/her health. 


Orange circle with the number four inside it, Safety Follow-up, lasts 8 weeks

Safety follow-up

(lasts 8 weeks)

Once your child finishes the Treatment Period, he/she will have the option to either join a separate long-term study called REJOIN or complete their participation with 1 final follow-up visit.

What types of tests and health checks will my child have at study visits?

Some of the tests and health checks include:

Icon of a stethoscope, Physical Exam

Physical exam

Icon of a blood pressure cuff, Blood Pressure

Blood pressure

Icon of a digital thermometer, Temperature

Temperature

Height

Icon of a scale, Weight

Weight

Icon of a magnifying glass next to an icon of a person's head, Neurological Exam

Neurological exam

Icon of a red heart icon, Heart Activity

Heart activity

Icon of a collection tube filled with red liquid representing blood, Blood Tests

Blood tests

Urine tests